Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation

被引:145
作者
Baron, F. [1 ]
Labopin, M. [2 ]
Niederwieser, D. [3 ]
Vigouroux, S. [4 ,5 ]
Cornelissen, J. J. [6 ]
Malm, C. [7 ]
Vindelov, L. L. [8 ]
Blaise, D. [9 ]
Janssen, J. J. W. M. [10 ]
Petersen, E. [11 ]
Socie, G. [12 ]
Nagler, A. [13 ]
Rocha, V. [14 ,15 ]
Mohty, M. [2 ,15 ,16 ,17 ]
机构
[1] Univ Liege, CHU Sart Tilman, Dept Hematol, B-4000 Liege, Belgium
[2] Hop St Antoine, Serv Hematol & Therapie Cellulaire, F-75571 Paris, France
[3] Univ Leipzig, Dept Hematol Oncol & Hemostasiol, Leipzig, Germany
[4] Univ Hosp, Dept Blood Dis, Bordeaux, France
[5] Univ Bordeaux 2, F-33076 Bordeaux, France
[6] Erasmus Univ, Med Ctr, Dept Hematol, Rotterdam, Netherlands
[7] Linkoping Univ, Linkoping, Sweden
[8] Rigshosp, Dept Hematol, DK-2100 Copenhagen, Denmark
[9] CHU Marseille, Dept Hematol, Marseille, France
[10] Vrije Univ Amsterdam, Dept Hematol, Med Ctr, Amsterdam, Netherlands
[11] Univ Med Ctr Utrecht, Dept Hematol, Utrecht, Netherlands
[12] Hop St Louis, Dept Bone Marrow Transplantat, Paris, France
[13] Tel Aviv Univ, Div Hematol, Tel Hashomer, Israel
[14] Eurocord, Paris, France
[15] EBMT ALWP, Paris, France
[16] Univ Nantes, CHU Hotel Dieu, Dept Hematol, Nantes, France
[17] INSERM, U892, Nantes, France
关键词
reduced-intensity conditioning; AML; GVHD; chronic; graft-versus-leukemia effects; ACUTE MYELOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; MYELODYSPLASTIC SYNDROME; COMPLETE REMISSION; SURVIVAL; MDS; AML; FLUDARABINE; MELPHALAN; ADULTS;
D O I
10.1038/leu.2012.135
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This report investigated the impact of graft-versus-host disease (GVHD) on transplantation outcomes in 1859 acute myeloid leukemia patients given allogeneic peripheral blood stem cells after reduced-intensity conditioning (RIC allo-SCT). Grade I acute GVHD was associated with a lower risk of relapse (hazards ratio (HR) 0.7, P = 0.02) translating into a trend for better overall survival (OS; HR 1.3; P = 0.07). Grade II acute GVHD had no net impact on OS, while grade III-IV acute GVHD was associated with a worse OS (HR 0.4, P < 0.0.001) owing to high risk of nonrelapse mortality (NRM; HR 5.2, P < 0.0001). In time-dependent multivariate Cox analyses, limited chronic GVHD tended to be associated with a lower risk of relapse (HR 0.72; P = 0.07) translating into a better OS (HR 1.8; P < 0.001), while extensive chronic GVHD was associated with a lower risk of relapse (HR 0.65; P = 0.02) but also with higher NRM (HR 3.5; P < 0.001) and thus had no net impact on OS. In-vivo T-cell depletion with antithymocyte globulin (ATG) or alemtuzumab was successful at preventing extensive chronic GVHD (P < 0.001), but without improving OS for ATG and even with worsening OS for alemtuzumab (HR 0.65; P = 0.001). These results highlight the role of the immune-mediated graft-versus-leukemia effect in the RIC allo-SCT setting, but also the need for improving the prevention and treatment of severe GVHD. Leukemia (2012) 26, 2462-2468; doi: 10.1038/leu.2012.135
引用
收藏
页码:2462 / 2468
页数:7
相关论文
共 35 条
[1]   Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT) [J].
Aoudjhane, M ;
Labopin, M ;
Gorin, NC ;
Shimoni, A ;
Ruutu, T ;
Kolb, HJ ;
Frassoni, F ;
Boiron, JM ;
Yin, JL ;
Finke, J ;
Shouten, H ;
Blaise, D ;
Falda, M ;
Fauser, AA ;
Esteve, J ;
Polge, E ;
Slavin, S ;
Niederwieser, D ;
Nagler, A ;
Rocha, V .
LEUKEMIA, 2005, 19 (12) :2304-2312
[2]   Haematopoietic cell transplantation as immunotherapy [J].
Appelbaum, FR .
NATURE, 2001, 411 (6835) :385-389
[3]   Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning [J].
Baron, F ;
Maris, MB ;
Sandmaier, BM ;
Storer, BE ;
Sorror, M ;
Diaconescu, R ;
Woolfrey, AE ;
Chauncey, TR ;
Flowers, MED ;
Mielcarck, M ;
Maloney, DG ;
Storb, R .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1993-2003
[4]   Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission [J].
Baron, Frederic ;
Storb, Rainer .
CURRENT OPINION IN HEMATOLOGY, 2007, 14 (02) :145-151
[5]   Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia [J].
Blaise, Didier ;
Vey, Norbert ;
Faucher, Catherine ;
Mohty, Mohamad .
HAEMATOLOGICA, 2007, 92 (04) :533-541
[6]   Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment [J].
Blaise, DP ;
Boiron, JM ;
Faucher, C ;
Mohty, M ;
Bay, JO ;
Bardoux, VJ ;
Perreau, V ;
Coso, D ;
Pigneux, A ;
Vey, N .
CANCER, 2005, 104 (09) :1931-1938
[7]   Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT [J].
Chevallier, P. ;
Labopin, M. ;
Milpied, N. ;
Cornelissen, J. J. ;
Blaise, D. ;
Petersen, E. ;
Sandstedt, A. ;
Goker, H. ;
Socie, G. ;
Rocha, V. ;
Mohty, M. .
BONE MARROW TRANSPLANTATION, 2012, 47 (11) :1442-1447
[8]   Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia [J].
Craddock, Charles ;
Nagra, Sandeep ;
Peniket, Andrew ;
Brookes, Cassandra ;
Buckley, Laura ;
Nikolousis, Emmanouil ;
Duncan, Nick ;
Tauro, Sudhir ;
Yin, John ;
Liakopoulou, Effie ;
Kottaridis, Panos ;
Snowden, John ;
Milligan, Donald ;
Cook, Gordon ;
Tholouli, Beni ;
Littlewood, Tint ;
Peggs, Karl ;
Vyas, Paresh ;
Clark, Fiona ;
Cook, Mark ;
MacKinnon, Stephen ;
Russell, Nigel .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (06) :989-995
[9]  
de Lima M, 2006, SEMIN HEMATOL, V43, P107, DOI 10.1053/j.seminhematol.2006.01.004
[10]   Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet [J].
Doehner, Hartmut ;
Estey, Elihu H. ;
Amadori, Sergio ;
Appelbaum, Frederick R. ;
Buechner, Thomas ;
Burnett, Alan K. ;
Dombret, Herve ;
Fenaux, Pierre ;
Grimwade, David ;
Larson, Richard A. ;
Lo-Coco, Francesco ;
Naoe, Tomoki ;
Niederwieser, Dietger ;
Ossenkoppele, Gert J. ;
Sanz, Miguel A. ;
Sierra, Jorge ;
Tallman, Martin S. ;
Loewenberg, Bob ;
Bloomfield, Clara D. .
BLOOD, 2010, 115 (03) :453-474